Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020

Haveri, Anu; Smura, Teemu; Kuivanen, Suvi; Österlund, Pamela; Hepojoki, Jussi; Ikonen, Niina; Pitkäpaasi, Marjaana; Blomqvist, Soile; Rönkkö, Esa; Kantele, Anu; Strandin, Tomas; Kallio-Kokko, Hannimari; Mannonen, Laura; Lappalainen, Maija; Broas, Markku; Jiang, Miao; Siira, Lotta; Salminen, Mika; Puumalainen, Taneli; Sane, Jussi

doi:10.2807/1560-7917.es.2020.25.11.2000266

Citations

Citation copied

Haveri, A., Smura, T., Kuivanen, S., Österlund, P., Hepojoki, J., Ikonen, N., Pitkäpaasi, M., Blomqvist, S., Rönkkö, E., Kantele, A., Strandin, T., Kallio-Kokko, H., Mannonen, L., Lappalainen, M., Broas, M., Jiang, M., Siira, L., Salminen, M., Puumalainen, T., … Savolainen-Kopra, C. (2020). Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Eurosurveillance, 25(11), 2000266. https://doi.org/10.2807/1560-7917.es.2020.25.11.2000266

Abstract

The first case of coronavirus disease (COVID-19) in Finland was confirmed on 29 January 2020. No secondary cases were detected. We describe the clinical picture and laboratory findings 3–23 days since the first symptoms. The SARS-CoV-2/Finland/1/2020 virus strain was isolated, the genome showing a single nucleotide substitution to the reference strain from Wuhan. Neutralising antibody response appeared within 9 days along with specific IgM and IgG response, targeting particularly nucleocapsid and spike proteins.